Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Necitumumab - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Necitumumab - Eli Lilly and Company

Alternative Names: IMC-11F8; LY 3012211; Portraza; Portrazza

Latest Information Update: 13 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImClone Systems
  • Developer AstraZeneca; Eli Lilly and Company
  • Class Antineoplastics; Fab fragments; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 30 May 2024 Eli Lilly and Company completes a phase III trial in Non-small cell lung cancer (First-line therapy, Combination therapy, Metastatic disease) in USA, Canada, Europe, Australia, Brazil, Belgium, Austria, Croatia, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia, Spain, the UK, Russia, South Korea, South Africa, Philippines, Singapore, Taiwan and Thailand (NCT00981058)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in France (IV, Infusion)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in Italy (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top